Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

HARMONY BIOSCIENCES HOLDINGS, INC.

(HRMY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Harmony Biosciences : HRMY Q2 2021BusinessUpdate-FINAL.pdf

08/10/2021 | 08:33am EST

Harmony Biosciences

Q2 2021 Financial and

Business Update

August 10, 2021

Legal Disclaimer

This presentation includes forwardlooking statements within the meaning of the Private Securities Reform Act of 1995. All statements other than statements of historical facts contained in these materials or elsewhere, including statements regarding Harmony Biosciences Holdings, Inc.'s (the "Company") future financial position, business strategy and plans and objectives of management for future operations, should be considered forward-looking statements. Forward-looking statements use words like "believes," "plans," "expects," "intends," "will," "would," "anticipates," "estimates," and similar words or expressions in discussions of the Company's future operations, financial performance or the Company's strategies. These statements are based on current expectations or objectives that are inherently uncertain, especially in light of the Company's limited operating history. These and other important factors discussed under the caption "Risk Factors" in the Company's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (the "SEC") on March 25, 2021 and its other filings with the SEC could cause actual results to differ materially and adversely from those indicated by the forward-looking statements made in this presentation. While the Company may elect to update such forward-looking statements at some point in the future, it disclaims any obligation to do so, even if subsequent events cause its views to change.

This presentation includes information related to market opportunity as well as cost and other estimates obtained from internal analyses and external sources. The internal analyses are based upon management's understanding of market and industry conditions and have not been verified by independent sources. Similarly, the externally sourced information has been obtained from sources the Company believes to be reliable, but the accuracy and completeness of such information cannot be assured. Neither the company, nor any of its respective officers, directors, managers, employees, agents, or representatives, (i) make any representations or warranties, express or implied, with respect to any of the information contained herein, including the accuracy or completeness of this presentation or any other written or oral information made available to any interested party or its advisor (and any liability therefore is expressly disclaimed), (ii) have any liability from the use of the information, including with respect to any forward-looking statements, or (iii) undertake to update any of the information contained herein or provide additional information as a result of new information or future events or developments.

2

Harmony's Strategy for Growth

Optimize

Expand

Acquire

WAKIX®

Clinical

New

Commercial

Utility of

Assets

Launch

WAKIX

3

Q2 2021 WAKIX Revenue Performance

Continued Growth with Q2 Revenue of $73.8M

$73.8

$56.3

$59.7

$45.6

$38.0

$19.8

$6.0

Q4 2019 Q1 2020 Q2 2020 Q3 2020 Q4 2020 Q1 2021 Q2 2021

2Q21

2Q21

2Q20

1Q21

2Q21

vs.

vs.

1Q21

2Q20

$38.0

$59.7

$73.8

23.6%

94%

Strong Revenue Growth in Q2 2021

  • 23.6% growth Q2 2021 vs. Q1 2021
  • Over 90% growth Q2 2021 vs. Q2 2020
  • Continued sequential quarter over quarter growth from launch

WAKIX Net Revenue ($m)

4

Driving Growth Through Our Launch For WAKIX Q2 2021 Performance

Increased

Access to HCPs

~3,200 Average # of

WAKIX Patients

Patient Outreach

Programs & Support

>37%

Of 8,000 unique HCPs have

prescribed WAKIX since launch

Healthcare Professional

Educational Initiatives

~80% U.S. Covered Lives With Formulary Access

Managed Care

Education & Outreach

5

This is an excerpt of the original content. To continue reading it, access the original document here.

Disclaimer

Harmony Biosciences Holdings Inc. published this content on 10 August 2021 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 10 August 2021 12:33:10 UTC.


ę Publicnow 2021
All news about HARMONY BIOSCIENCES HOLDINGS, INC.
12/01Harmony Biosciences to Conduct Phase 3 Trial of Pitolisant for Treatment of Idiopathic ..
MT
12/01Oppenheimer Initiates Harmony Biosciences With Outperform Rating, $55 Price Target
MT
12/01Harmony Biosciences Announces Plans To Initiate Phase 3 Clinical Trial For Treatment Of..
PR
12/01Harmony Biosciences Holdings, Inc. Announces Plans To Initiate Phase 3 Clinical Trial F..
CI
11/22HARMONY BIOSCIENCES : APPOINTS LINDA SZYPER TO ITS BOARD OF DIRECTORS - Form 8-K
PU
11/22HARMONY BIOSCIENCES HOLDINGS, INC. : Change in Directors or Principal Officers, Regulation..
AQ
11/22Harmony Biosciences Appoints Linda Szyper To Its Board Of Directors
PR
11/22Harmony Biosciences Holdings, Inc. Appoints Linda Szyper to Board of Directors
CI
11/18INSIDER SELL : Harmony Biosciences Holdings
MT
11/11Harmony Biosciences To Participate In Two Investor Conferences In November
PR
More news
Analyst Recommendations on HARMONY BIOSCIENCES HOLDINGS, INC.
More recommendations
Financials (USD)
Sales 2021 306 M - -
Net income 2021 38,5 M - -
Net cash 2021 12,0 M - -
P/E ratio 2021 60,7x
Yield 2021 -
Capitalization 2 315 M 2 315 M -
EV / Sales 2021 7,54x
EV / Sales 2022 4,58x
Nbr of Employees 150
Free-Float 79,9%
Chart HARMONY BIOSCIENCES HOLDINGS, INC.
Duration : Period :
Harmony Biosciences Holdings, Inc. Technical Analysis Chart | HRMY | US4131971040 | MarketScreener
Technical analysis trends HARMONY BIOSCIENCES HOLDINGS, INC.
Short TermMid-TermLong Term
TrendsNeutralBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Last Close Price 39,60 $
Average target price 57,00 $
Spread / Average Target 43,9%
EPS Revisions
Managers and Directors
John C.s Jacobs President, Chief Executive Officer & Director
Sandipkumar S. Kapadia Chief Financial Officer
Jeffrey S. Aronin Non-Executive Chairman
Jeffrey M. Dayno Chief Medical Officer
David Bradshaw Head-Technical Operations
Sector and Competitors
1st jan.Capi. (M$)
HARMONY BIOSCIENCES HOLDINGS, INC.9.54%2 315
JOHNSON & JOHNSON4.42%432 641
ROCHE HOLDING AG20.68%329 493
PFIZER, INC.39.64%288 501
NOVO NORDISK A/S73.12%256 630
ELI LILLY AND COMPANY45.17%221 499